Lilly's triple-acting obesity drug hits goal in Phase 3 trial
An article from Dive Brief // Obesity drugs Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk. Published May 21,…
Read guide →